Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phospholipase A2 group IIA (PLA2G2A) is a low-molecular-weight secretory enzyme that plays a fundamental role in lipid metabolism and the systemic inflammatory cascade (UniProt P14555). It catalyzes the calcium-dependent hydrolysis of the sn-2 ester bond of phospholipids, releasing free fatty acids like arachidonic acid and lysophospholipids, which are precursors for pro-inflammatory eicosanoids such as prostaglandins and leukotrienes (PubMed: 2925633). Beyond its metabolic function, PLA2G2A acts as a critical component of the innate immune system by exhibiting potent bactericidal activity against Gram-positive bacteria through direct membrane disruption (PubMed: 11134015). High circulating levels of the enzyme are established biomarkers for disease severity in conditions like sepsis, rheumatoid arthritis, and acute coronary syndrome (PubMed: 23143307). In oncology, its role is context-dependent; while it acts as a tumor suppressor in colorectal cancer (associated with the MOM1 locus), it is often upregulated in other cancers like prostate and pancreatic cancer, where it contributes to tumor progression and immune evasion (MDPI: 10.3390/cells11050882). Therapeutic strategies have primarily utilized small-molecule inhibitors such as varespladib (LY315920) and its prodrug methyl-varespladib (LY333013), though these have faced clinical challenges including a lack of efficacy in large-scale trials and potential safety signals regarding cardiovascular events (NIH/PubChem). Despite these setbacks, it remains a target of interest for its dual role in mediating systemic inflammation and managing the host microbiota (PubMed: 35073105).
Competitive inhibition of the enzyme's catalytic active site, preventing the hydrolysis of membrane phospholipids and the subsequent release of pro-inflammatory lipid precursors.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phospholipase A2 group IIA (PLA2G2A) (PLA2G2A).